Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.56 - $15.21 $812,748 - $3.47 Million
228,300 Added 685.59%
261,600 $3.98 Million
Q2 2024

Aug 15, 2024

SELL
$4.63 - $7.09 $200,016 - $306,288
-43,200 Reduced 56.47%
33,300 $158,000
Q1 2024

May 07, 2024

SELL
$3.61 - $6.88 $329,593 - $628,144
-91,300 Reduced 54.41%
76,500 $519,000
Q4 2023

Feb 14, 2024

BUY
$2.71 - $5.08 $168,291 - $315,468
62,100 Added 58.75%
167,800 $820,000
Q3 2023

Nov 14, 2023

BUY
$3.42 - $7.85 $218,880 - $502,400
64,000 Added 153.48%
105,700 $361,000
Q2 2023

Aug 11, 2023

SELL
$3.76 - $5.05 $16,167 - $21,715
-4,300 Reduced 9.35%
41,700 $199,000
Q1 2023

May 16, 2023

SELL
$3.78 - $5.03 $77,112 - $102,612
-20,400 Reduced 30.72%
46,000 $194,000
Q4 2022

Feb 14, 2023

SELL
$3.36 - $6.55 $164,976 - $321,605
-49,100 Reduced 42.51%
66,400 $256,000
Q3 2022

Nov 14, 2022

SELL
$3.61 - $6.08 $93,860 - $158,080
-26,000 Reduced 18.37%
115,500 $693,000
Q2 2022

Aug 15, 2022

SELL
$2.89 - $4.51 $6,358 - $9,922
-2,200 Reduced 1.53%
141,500 $494,000
Q1 2022

May 16, 2022

BUY
$2.83 - $5.68 $345,543 - $693,528
122,100 Added 565.28%
143,700 $493,000
Q4 2021

Feb 14, 2022

SELL
$2.89 - $4.16 $429,454 - $618,176
-148,600 Reduced 87.31%
21,600 $63,000
Q3 2021

Nov 15, 2021

BUY
$3.8 - $5.23 $510,720 - $702,912
134,400 Added 375.42%
170,200 $684,000
Q1 2021

May 17, 2021

SELL
$3.63 - $7.93 $131,769 - $287,859
-36,300 Reduced 50.35%
35,800 $168,000
Q4 2020

Feb 16, 2021

BUY
$3.43 - $5.23 $91,924 - $140,164
26,800 Added 59.16%
72,100 $247,000
Q3 2020

Nov 16, 2020

BUY
$4.08 - $9.81 $184,824 - $444,393
45,300 New
45,300 $238,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $320M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.